This clinical-stage biotech develops targeted oral therapies for RAS/MAPK-driven cancers, with all assets currently in development.
Why This Fund Made a $189 Million Bet on Erasca as Shares Skyrocket 800%
Source: Fool - Investing News
More ERAS News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Erasca, Inc. - ERAS
GlobeNewsWire·11 days ago
ERASCA INVESTOR ALERT: Bragar Eagel & Squire, P.C. is Investigating Erasca, Inc. on Behalf of Erasca Stockholders and Encourages Investors to Contact the Firm
GlobeNewsWire·16 days ago
Erasca, Inc. (ERAS) Discusses Preliminary Phase I Data and Differentiation of Pan-RAS Molecular Glue ERAS-0015 Transcript
Seeking Alpha·2026-04-27